The stock of Innocoll Holdings PLC (NASDAQ:INNL) is a huge mover today! About 371,993 shares traded hands or 296.19% up from the average. Innocoll Holdings PLC (NASDAQ:INNL) has declined 56.25% since April 4, 2016 and is downtrending. It has underperformed by 57.34% the S&P500.
The move comes after 7 months negative chart setup for the $94.50 million company. It was reported on Nov, 4 by Barchart.com. We have $2.79 PT which if reached, will make NASDAQ:INNL worth $10.40 million less.
Innocoll Holdings PLC (NASDAQ:INNL) Ratings Coverage
Out of 2 analysts covering Innocoll AG (NASDAQ:INNL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Innocoll AG has been the topic of 3 analyst reports since April 28, 2016 according to StockzIntelligence Inc. Janney Capital initiated Innocoll Holdings PLC (NASDAQ:INNL) rating on Thursday, April 28. Janney Capital has “Buy” rating and $15 price target. FBR Capital maintained the stock with “Outperform” rating in Friday, November 4 report. The firm has “Outperform” rating given on Thursday, June 30 by FBR Capital.
According to Zacks Investment Research, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland.”
More notable recent Innocoll Holdings PLC (NASDAQ:INNL) news were published by: Globenewswire.com which released: “Innocoll Holdings plc Announces Closing of Public Offering” on June 22, 2016, also Globenewswire.com with their article: “Innocoll Holdings plc Announces Second Quarter 2016 Financial and Operating …” published on August 17, 2016, Globenewswire.com published: “Innocoll Holdings plc Appoints Lesley Russell, MBChB, MRCP, as Chief Medical …” on April 20, 2016. More interesting news about Innocoll Holdings PLC (NASDAQ:INNL) were released by: Globenewswire.com and their article: “Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal …” published on June 23, 2016 as well as Marketwatch.com‘s news article titled: “Innocoll started at outperform with $18 stock price target at FBR & Co.” with publication date: July 25, 2014.
INNL Company Profile
Innocoll Holdings Public Limited Company, incorporated on May 28, 2014, is a commercial-stage specialty pharmaceutical and medical device firm with late-stage development programs. The Firm operates through the segment of manufacture and sale of collagen pharmaceutical products. The Firm utilizes its collagen technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, the Company derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.